| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Eikon Therapeutics, Inc. (EIKN) has 4 insiders with recent SEC Form 4 filings, including 8 buys and 0 sells. EIKN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.36M | $13.71M | - | |
| 10% | 1.29M | $13.01M | - | |
| 10% | 697.9K | $7.03M | - | |
| 10% | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | Column Group IV Gp, LP | 10% Owner | Buy | 2,117,760 | $18.00 | $38,119,680.00 | +57.8% | |
| Feb 4, 2026 | Wolfe Josh | Director, 10% Owner | Buy | 277,776 | $18.00 | $4,999,968.00 | New | |
| Feb 4, 2026 | Lux Venture Partners V, LLC | 10% Owner | Buy | 277,776 | $18.00 | $4,999,968.00 | New | |
| Feb 4, 2026 | Foresite Capital Management Iv, LLC | 10% Owner | Buy | 55,555 | $18.00 | $999,990.00 | +4.4% |